drugset / Trial / NCT01978028

Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose

NCT01978028

Phase 4 Terminated 20 enrolled University of Zurich
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary efficacy objective of this study is to evaluate the effect of ferric carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment.

Timeline

Start
2013-10
Primary completion
2017-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferric carboxymaltose Other / unclassified

Indications